Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Expert discussion on metastatic castration resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.05.18
Views: 1904

Prof Heather Payne and Dr Luis Martinez-Piñeiro

Professor Payne and Dr Luis Martinez-Piñeiro discuss the key topics presented at the 13th Prostate Cancer Debate in Madrid, with a focus on metastatic castration resistant prostate cancer (mCRPC).

They talk around the available therapy options and the sequencing of treatment for this group of patients, sharing their opinions on rechallenging and the tolerability of the available therapy options. They also discuss the St Gallen Consensus and their interest in the variability of practice for treating patients with CRPC around the world.

Professor Payne and Dr Martinez-Piñeiro also discuss the treatment of geriatric patients and share views on the idea that treatment decisions should be more focused on co-morbidities than age.

Treatment after disease relapse
Quality of life and reported toxicities
Best practice outside of guidelines
Prostate cancer in the elderly

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation